X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alirocumab (309) 309
index medicus (198) 198
evolocumab (147) 147
humans (143) 143
hypercholesterolemia (138) 138
pcsk9 (126) 126
safety (115) 115
efficacy (113) 113
cholesterol (103) 103
cardiac & cardiovascular systems (102) 102
statins (99) 99
monoclonal-antibody (90) 90
heterozygous familial hypercholesterolemia (86) 86
pharmacology & pharmacy (82) 82
antibodies, monoclonal - therapeutic use (70) 70
density-lipoprotein cholesterol (69) 69
proprotein convertase 9 - antagonists & inhibitors (69) 69
cholesterol, ldl - blood (68) 68
cardiovascular disease (64) 64
hypercholesterolemia - drug therapy (64) 64
lipids (61) 61
anticholesteremic agents - therapeutic use (60) 60
familial hypercholesterolemia (60) 60
reducing lipids (58) 58
low density lipoproteins (54) 54
male (54) 54
statin therapy (54) 54
subtilisin/kexin type 9 (54) 54
middle aged (53) 53
female (52) 52
ldl cholesterol (47) 47
ldl-c (46) 46
treatment outcome (46) 46
cardiovascular diseases (45) 45
pcsk9 inhibitors (45) 45
risk factors (45) 45
ezetimibe (44) 44
monoclonal antibodies (44) 44
low-density lipoprotein cholesterol (43) 43
double-blind (42) 42
lipoproteins (42) 42
low density lipoprotein (41) 41
aged (39) 39
atherosclerosis (39) 39
inhibitor alirocumab (37) 37
therapy (37) 37
hypercholesterolemia - blood (35) 35
risk (35) 35
antibodies, monoclonal - adverse effects (34) 34
proprotein convertase 9 (34) 34
evolocumab amg 145 (33) 33
kexin (33) 33
subtilisin (32) 32
cardiovascular (31) 31
cardiovascular diseases - prevention & control (31) 31
clinical trials (31) 31
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (31) 31
peripheral vascular disease (31) 31
atorvastatin (30) 30
coronary-heart-disease (30) 30
double-blind method (30) 30
patients (29) 29
cardiovascular events (28) 28
management (28) 28
proprotein convertase 9 - metabolism (28) 28
care and treatment (27) 27
drug therapy (27) 27
hyperlipoproteinemia type ii - drug therapy (27) 27
ldl-cholesterol (27) 27
cardiovascular risk (26) 26
cardiovascular-risk patients (26) 26
diabetes (26) 26
placebo-controlled trial (26) 26
proprotein convertase subtilisin/kexin type 9 (26) 26
adult (25) 25
antibodies, monoclonal - administration & dosage (25) 25
randomized controlled-trial (25) 25
anticholesteremic agents - adverse effects (23) 23
dyslipidemia (23) 23
acute coronary syndromes (22) 22
endocrinology & metabolism (22) 22
metaanalysis (22) 22
proprotein convertase subtilisin (22) 22
statin intolerance (22) 22
abridged index medicus (21) 21
animals (21) 21
biomarkers - blood (21) 21
drug therapy, combination (21) 21
monoclonal antibody (21) 21
prevention (21) 21
proprotein convertases - antagonists & inhibitors (21) 21
analysis (20) 20
cardiology (20) 20
cholesterol, ldl (20) 20
disease (20) 20
bococizumab (19) 19
medicine, general & internal (19) 19
research (19) 19
statin-intolerant patients (19) 19
cardiovascular-disease (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (321) 321
Spanish (11) 11
German (8) 8
Czech (2) 2
Russian (2) 2
French (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 244, pp. 138 - 146
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2019, Volume 73, Issue 4, pp. 387 - 396
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with... 
alirocumab | total events | acute coronary syndrome
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 07/2019, Volume 13, Issue 4, pp. 586 - 593.e5
Differences in lipid and cardiovascular risk profiles have been observed in African-American/black (AA/B), white (W), and Hispanic/Latino (H/L) individuals.... 
PCSK9 | Ethnicity | Alirocumab | Race | Atherosclerosis | Index Medicus
Journal Article
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, ISSN 0920-3206, 2016, Volume 30, Issue 5, pp. 473 - 483
Journal Article
Revista Espanola de Cardiologia, ISSN 0300-8932, 12/2018, Volume 71, Issue 12, pp. 1010 - 1017
Introduction and objectives: PCSK9 inhibitors (PCSK9i) are safe and effective lipid-lowering drugs. Their main limitation is their high cost. The aim of this... 
PCSK9 inhibitors | Alirocumab/evolocumab | Therapeutic indication | Low-density lipoprotein cholesterol
Journal Article
Diabetes & Metabolism, ISSN 1262-3636, 2017, Volume 43, Issue 5, pp. 453 - 459
Abstract Aims The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires... 
Internal Medicine | Endocrinology & Metabolism | PCSK9 | ODYSSEY | Alirocumab | Diabetes | LDL-C | Insulin | RANDOMIZED-TRIALS | ACUTE CORONARY SYNDROMES | MONOCLONAL-ANTIBODY | MELLITUS | INHIBITOR ALIROCUMAB | DENSITY-LIPOPROTEIN CHOLESTEROL | STATIN THERAPY | DISEASE | ENDOCRINOLOGY & METABOLISM | OUTCOMES TRIAL | DYSLIPIDEMIA | Index Medicus
Journal Article
Atherosclerosis, ISSN 0021-9150, 2016, Volume 254, pp. 254 - 262
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2019, Volume 74, Issue 9, pp. 1167 - 1176
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and... 
major adverse cardiac events | alirocumab | acute coronary syndrome | cerebrovascular disease | peripheral artery disease | death
Journal Article
European heart journal, ISSN 0195-668X, 05/2019, Volume 40, Issue 33, pp. 2801 - 2809
The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen... 
Index Medicus | Prevention | MI types | Alirocumab | Mortality | Fast Track Clinical Research
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 05/2018, Volume 12, Issue 3, pp. 662 - 668
The alirocumab expanded use program provided open-label access to alirocumab before its commercial availability to patients with severe hypercholesterolemia... 
Expanded use | PCSK9 inhibitor | LDL-C | ODYSSEY | Alirocumab | Heterozygous familial hypercholesterolemia | Coronary heart disease | Statin intolerance | EFFICACY | SAFETY | MONOCLONAL-ANTIBODY | EZETIMIBE | INHIBITOR ALIROCUMAB | THERAPY | PHARMACOLOGY & PHARMACY
Journal Article
Atherosclerosis, ISSN 0021-9150, 09/2019, Volume 288, pp. 194 - 202
Elevated lipoprotein(a) [Lp(a)] levels are considered a causal factor for cardiovascular disease. In phase 3 ODYSSEY trials, alirocumab reduced levels of... 
Cholesterol-lowering drugs | PCSK9 | Alirocumab | lipoprotein(a) | Low-density lipoprotein cholesterol | Cardiovascular risk
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 01/2019, Volume 13, Issue 1, pp. 138 - 147
Patients with heterozygous familial hypercholesterolemia (HeFH) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled in the... 
PCSK9 | Alirocumab | Familial hypercholesterolemia | Open-label extension | LDL-C | MANAGEMENT | EFFICACY | SAFETY | GUIDELINES | CARDIOVASCULAR-RISK PATIENTS | EZETIMIBE | hypercholesterolemia | INHIBITOR ALIROCUMAB | ATORVASTATIN | Familial | PHARMACOLOGY & PHARMACY | ASSOCIATION | ROSUVASTATIN
Journal Article
Journal of Pharmacy Practice, ISSN 0897-1900, 2018, pp. 897190018799218 - 897190018799218
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower atherogenic lipid markers in patients with statin intolerance;... 
PCSK9 inhibitors | alirocumab | myalgia | statin intolerance | evolocumab
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2019, Volume 105, Issue 2, pp. 496 - 504
In randomized clinical trials ( RCT s) proprotein convertase subtilisin/kexin 9 ( PCSK 9) inhibitors showed a favorable safety profile, however, “real‐world”... 
ANTIBODIES | DRUG-REACTIONS | TRIALS | ALIROCUMAB | METAANALYSIS | EFFICACY | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HYPERCHOLESTEROLEMIA | EVOLOCUMAB | Research
Journal Article